We use cookies to ensure you get the best experience on our website. Learn more about our privacy policy.
Attention
This is an external link. Click “OK” to continue.
Building a pipeline of anti-inflammatory drugs
Our lead drug, otenaproxesul, is in clinical development for acute pain. Our second pipeline drug, ATB-352, addresses unmet needs in a specialized pain indication. In addition to an ongoing program to fortify the IP position of our drugs and platform, Antibe’s Emerging Discovery Program is developing a new molecule to target inflammatory bowel disease (“IBD”).
DEVELOPMENT PIPELINE
Click on a therapeutic candidate to learn more.
INVESTOR INFORMATION
Keep up-to-date—visit the Investor Dashboard for share information, our Corporate Presentation, financial statements, regulatory filings, the latest news and more—everything you need in one place.
OUR SCIENCE
Learn about the science behind our drug platform. See how Antibe’s lead drug aims to surpass current treatments. Investigate a diagram detailing hydrogen sulfide’s multiple roles in the human body.